|Bid||0.0950 x 0|
|Ask||0.1000 x 0|
|Day's Range||0.0950 - 0.1100|
|52 Week Range||0.0950 - 0.3200|
|Beta (5Y Monthly)||1.43|
|PE Ratio (TTM)||0.15|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul. 21, 2005|
|1y Target Est||N/A|
Quest PharmaTech Inc. (TSXV: QPT) ("Quest") wishes to provide a further update regarding the final payment to be made pursuant to the Immunotherapy Asset Transfer between 45% owned OncoQuest Inc. ("OncoQuest") and OncoQuest Pharmaceuticals, Inc. (formerly Dual Industrial Co., Ltd.) (KOSDAQ: 078590 or 078590.KQ) ("OQP"). A second closing of the transaction has now occurred at which time all legal title and registrations for OncoQuest's immunotherapy assets were transferred to OQP. Under the terms of the transaction, the second closing entitled OncoQuest to receive the final payment of 65,229,709 shares of OQP with an ascribed value in the transaction of USD$175 million, subject to all required regulatory approvals. Although OncoQuest and OQP management continue to work diligently, Korean regulatory approval for the share payment has been further delayed and still has not been received. The delay relates to the audited financial statements for its most recently completed financial year. This delay has also resulted in trading in the shares of OQP on the KOSDAQ Exchange being halted effective March 24, 2021. It remains uncertain at this time as to whether regulatory approval will ultimately be received or the timing of any such approval.
TSX Venture: QPT EDMONTON, AB, Nov. 9, 2020 /CNW/ - Quest PharmaTech Inc.
EDMONTON, AB , June 4, 2020 /CNW/ - Quest PharmaTech Inc. (QPT.V) ("Quest" or the "Company") wishes to provide a corporate update following the entering into of the asset transfer transaction between 40% owned OncoQuest Inc. ("OncoQuest") and Korean publicly traded Dual Industrial Co., Ltd.(078590.KQ) ('Dual") and the first closing under that transaction. A second closing of the transaction will occur upon completion of all transfers of legal title and registrations for OncoQuest's immunotherapy assets to Dual, which is expected to occur no later than December 31, 2020 . A minimum of US$62.5 million of these bonds may be redeemed for cash not later than December 31, 2020 and would be used by OncoQuest, in part, to pay for the costs of the transaction, including income taxes.